Yonkenafil (Tunodafil) is a potent, selective PDE5 inhibitor with IC50 of 2.0 nM.
Yonkenafil inhibits microglial activation by decreasing PDE-5 expression and increasing the cGMP level.
Yonkenafil induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke.
Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP/PS1 transgenic mice model.
